Updates
News
Latest news posts
Why Fast Track designation Matters The Fast Track designation is awarded by the FDA to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. For our team, it means increased interaction with FDA experts throughout the development process, allowing us to gain early feedback on crucial steps, such … Continued
Series C round co-led by R42 Group and Atomico, and joined by new/current investors; Financing to advance expanding rare disease pipeline U.S. FDA has cleared its investigational new drug (IND) application to advance HLX-1502 in Phase 2 clinical trial in NF1; Healx to initiate Phase 2 clinical trial by end of year Healx, co-founded by … Continued